Who
Robert F. Williamson III
Director
Company insider
Files Form 4 as: Director, Perspective Therapeutics; Director, Pharmasset.
In numbers
- Trades disclosed
- 57
- Buys
- 14
- Sells
- 1
- Bought
- $494K
- Sold
- $3.3M
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 10 Oct 2007
- Last trade
- 2 Mar 2026
- Last filed
- 4 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Mar 2026filed 4 Mar 2026 | CATX Perspective Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | CATX Perspective Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 12 Nov 2025filed 14 Nov 2025 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Bought | $20K9,498 at $2.10 | filing |
| 31 Mar 2025filed 1 Apr 2025 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Bought | $82K38,145 at $2.14 | filing |
| 28 Mar 2025filed 1 Apr 2025 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Bought | $50K22,192 at $2.27 | filing |
| 3 Mar 2025filed 5 Mar 2025 | CATX Perspective Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 25 Nov 2024filed 27 Nov 2024 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Bought | $13K3,647 at $3.62 | filing |
| 25 Nov 2024filed 27 Nov 2024 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Bought | $9,6122,619 at $3.67 | filing |
| 20 Jun 2024filed 24 Jun 2024 | CATX Perspective Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,000 at $0.00 | filing |
| 31 May 2024filed 3 Jun 2024 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Bought | $76K55,000 at $1.38 | filing |
| 29 May 2024filed 30 May 2024 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Bought | $15K11,375 at $1.32 | filing |
| 29 May 2024filed 30 May 2024 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Bought | $25K18,656 at $1.34 | filing |
| 30 Jan 2024filed 1 Feb 2024 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Bought | $13K18,579 at $0.71 | filing |
| 30 Jan 2024filed 1 Feb 2024 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Bought | $3,6405,127 at $0.71 | filing |
| 30 Jan 2024filed 1 Feb 2024 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Bought | $41K57,121 at $0.71 | filing |
| 30 Jan 2024filed 1 Feb 2024 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Bought | $31K42,879 at $0.72 | filing |
| 30 Jan 2024filed 1 Feb 2024 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Bought | $2,4503,500 at $0.70 | filing |
| 29 Jan 2024filed 30 Jan 2024 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Bought | $2,5804,031 at $0.64 | filing |
| 29 Jan 2024filed 30 Jan 2024 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Bought | $14K21,235 at $0.64 | filing |
| 26 Jan 2024filed 30 Jan 2024 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Bought | $7,47312,250 at $0.61 | filing |
News
No headline names them, or the companies they trade most, lately.